EUCTR2021-001414-10-NL进行中（未招募）1 期
Vaccine response against SARS-CoV-2 in patients with primary Sjögren’s syndrome - VaccineSS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age 18-75 years
- •Written informed consent
- •Fulfilment of 2016 ACR-EULAR criteria (for pSS patients)
- •Female sex (for healthy volunteers)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 135
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •Confirmed SARS-CoV-2 infection (current or previous)
- •Women who are pregnant (self-reported, participants will be asked -when in doubt- to perform a pregnancy test before study entry)
- •Current use of prednisone >10mg/day, conventional DMARDs (except hydroxychloroquine) or biological DMARDS. Previous use of DMARDs =6 months before inclusion (=12 months for rituximab) is allowed.
研究者
相似试验
已完成
4 期
Vaccine response against SARS-CoV-2 in patients with primary Sjögren*s syndrome1000381610047438Sjögren's syndromeNL-OMON51179niversitair Medisch Centrum Groningen180
进行中（未招募）
1 期
SARS-CoV-2 vaccination response in patients with haematologicaldiseaseEUCTR2021-001107-33-NLMUMC743
已完成
Unknown
Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients on Disease-Modifying DrugsMultiple SclerosisJPRN-UMIN000049478Osaka University Department of Neurology, Osaka University Graduate School of Medicine50
进行中（未招募）
1 期
Response to Covid-19 vaccination in patients with cancerImmune response to Covid-19 vaccination of patients with immune modulatory treatment for cancerEUCTR2021-000905-26-SEDepartment of Oncology, Uppsala University Hospita150
已完成
不适用
SARS-CoV-2 specific immunity in patients with congenital immune deficienciesNL-OMON50905Academisch Medisch Centrum15